Segment, Geographic and Other Revenue Information (Tables)
|
12 Months Ended |
Dec. 31, 2019 |
|---|
| Segment Reporting [Abstract] |
|
| Reconciliation of Revenue from Segments to Consolidated |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | The following table provides selected income statement information by reportable segment: | | | Revenues | | Earnings(a) | | Depreciation and Amortization(b) | | | Year Ended December 31, | | Year Ended December 31, | | Year Ended December 31, | (MILLIONS OF DOLLARS) | | 2019 |
| | 2018 |
| | 2017 |
| | 2019 |
| | 2018 |
| | 2017 |
| | 2019 |
| | 2018 |
| | 2017 |
| Reportable Segments: | | | | | | | | | | | | | | | | | | | Biopharma | | $ | 39,419 |
| | $ | 37,558 |
| | $ | 35,530 |
| | $ | 24,517 |
| | $ | 23,738 |
| | $ | 22,194 |
| | $ | 958 |
| | $ | 953 |
| | $ | 881 |
| Upjohn | | 10,233 |
| | 12,484 |
| | 13,447 |
| | 6,785 |
| | 8,636 |
| | 9,348 |
| | 105 |
| | 112 |
| | 125 |
| Total reportable segments | | 49,653 |
| | 50,042 |
| | 48,977 |
| | 31,301 |
| | 32,374 |
| | 31,542 |
| | 1,063 |
| | 1,065 |
| | 1,006 |
| Other business activities | | 2,098 |
| | 3,605 |
| | 3,472 |
| | (5,723 | ) | | (5,283 | ) | | (5,302 | ) | | 108 |
| | 146 |
| | 142 |
| Reconciling Items: | | | | | | | | |
| | |
| |
|
| |
|
| |
|
| |
|
| Corporate and other unallocated | | — |
| | — |
| | 97 |
| | (5,859 | ) | | (6,383 | ) | | (6,299 | ) | | 453 |
| | 503 |
| | 465 |
| Purchase accounting adjustments | | — |
| | — |
| | — |
| | (4,333 | ) | | (4,786 | ) | | (4,758 | ) | | 4,347 |
| | 4,620 |
| | 4,565 |
| Acquisition-related costs | | — |
| | — |
| | — |
| | (185 | ) | | (318 | ) | | (456 | ) | | 3 |
| | 12 |
| | 39 |
| Certain significant items(c) | | — |
| | — |
| | — |
| | 2,481 |
| | (3,719 | ) | | (2,423 | ) | | 36 |
| | 38 |
| | 52 |
| | | $ | 51,750 |
| | $ | 53,647 |
| | $ | 52,546 |
| | $ | 17,682 |
| | $ | 11,885 |
| | $ | 12,305 |
| | $ | 6,010 |
| | $ | 6,384 |
| | $ | 6,269 |
|
| | (a) | Income from continuing operations before provision/(benefit) for taxes on income. Biopharma’s earnings include dividend income from our investment in ViiV of $220 million in 2019, $253 million in 2018 and $266 million in 2017. For additional information, see Note 4. |
| | (b) | Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations. |
| | (c) | Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. |
For Earnings in 2019, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $758 million, (ii) charges for certain legal matters of $543 million, (iii) certain asset impairment charges of $2.8 billion, (iv) charges for business and legal entity alignment of $495 million, (v) net gains of $415 million recognized during the period on equity securities, (vi) a pre-tax gain of $8.1 billion associated with the completion of the GSK Consumer Healthcare joint venture transaction, (vii) net losses on early retirement of debt of $138 million and (viii) other charges of $1.3 billion, which includes, among other things: an upfront license fee payment of $250 million to Akcea, which was recorded in Research and development expenses, charges of $112 million recorded in Other (income)/deductions––net representing our pro rata share of primarily restructuring and business combination accounting charges recorded by the GSK Consumer Healthcare joint venture, a $337 million charge in Research and development expenses related to our acquisition of Therachon, a $99 million charge in Cost of sales related to rivipansel, primarily for inventory manufactured for expected future sale and charges of $240 million, primarily in Selling, informational and administrative expenses and Other (income)/deductions––net, for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity associated with the formation of the GSK Consumer Healthcare joint venture. For additional information, see Note 1A, Note 2A, Note 2C, Note 2D, Note 3 and Note 4. For Earnings in 2018, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $977 million, (ii) net charges for certain legal matters of $157 million, (iii) certain asset impairment charges of $3.1 billion, (iv) charges for business and legal entity alignment of $63 million, (v) net gains of $586 million recognized during the period on equity securities, (vi) net losses on early retirement of debt of $3 million and (vii) other charges of $4 million, which includes, among other things: a non-cash $343 million pre-tax gain in Other (income)/deductions––net associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and pre-clinical stage neuroscience assets primarily targeting disorders of the central nervous system, a $119 million charge, in the aggregate, in Selling, informational and administrative expenses for a special, one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected positive net impact of the December 2017 enactment of the TCJA, and a non-cash $50 million pre-tax gain in Other (income)/deductions––net as a result of the contribution of our allogeneic CAR T cell therapy development program assets in connection with our contribution agreement entered into with Allogene. For additional information, see Note 2B, Note 3 and Note 4. For Earnings in 2017, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $204 million, (ii) charges for certain legal matters of $237 million, (iii) certain asset impairment charges of $379 million, (iv) charges for business and legal entity alignment of $71 million, (v) net gains of $224 million recognized during the period on equity securities, (vi) net losses on early retirement of debt of $999 million and (vii) other charges of $756 million, which includes, among other things: a charitable contribution to the Pfizer Foundation of $200 million, which is included in Selling, informational and administrative expenses, $195 million in inventory losses, overhead costs related to the period in which our Puerto Rico plants were not operational, and incremental costs, all of which resulted from hurricanes in Puerto Rico in 2017 and are included in Cost of sales, an $81 million loss related to the sale of our former 49% equity share in Hisun Pfizer, which is included in Other (income)/deductions––net, charges of $55 million in Other (income)/deductions––net representing adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell and a net loss of $30 million related to the sale of our former 40% ownership investment in Teuto, including the extinguishment of a put option for the remaining 60% ownership interest, which is included in Other (income)/deductions––net. For additional information, see Note 2B, Note 2C, Note 3 and Note 4.
|
| Reconciliation of Operating Profit (Loss) from Segments to Consolidated |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | The following table provides selected income statement information by reportable segment: | | | Revenues | | Earnings(a) | | Depreciation and Amortization(b) | | | Year Ended December 31, | | Year Ended December 31, | | Year Ended December 31, | (MILLIONS OF DOLLARS) | | 2019 |
| | 2018 |
| | 2017 |
| | 2019 |
| | 2018 |
| | 2017 |
| | 2019 |
| | 2018 |
| | 2017 |
| Reportable Segments: | | | | | | | | | | | | | | | | | | | Biopharma | | $ | 39,419 |
| | $ | 37,558 |
| | $ | 35,530 |
| | $ | 24,517 |
| | $ | 23,738 |
| | $ | 22,194 |
| | $ | 958 |
| | $ | 953 |
| | $ | 881 |
| Upjohn | | 10,233 |
| | 12,484 |
| | 13,447 |
| | 6,785 |
| | 8,636 |
| | 9,348 |
| | 105 |
| | 112 |
| | 125 |
| Total reportable segments | | 49,653 |
| | 50,042 |
| | 48,977 |
| | 31,301 |
| | 32,374 |
| | 31,542 |
| | 1,063 |
| | 1,065 |
| | 1,006 |
| Other business activities | | 2,098 |
| | 3,605 |
| | 3,472 |
| | (5,723 | ) | | (5,283 | ) | | (5,302 | ) | | 108 |
| | 146 |
| | 142 |
| Reconciling Items: | | | | | | | | |
| | |
| |
|
| |
|
| |
|
| |
|
| Corporate and other unallocated | | — |
| | — |
| | 97 |
| | (5,859 | ) | | (6,383 | ) | | (6,299 | ) | | 453 |
| | 503 |
| | 465 |
| Purchase accounting adjustments | | — |
| | — |
| | — |
| | (4,333 | ) | | (4,786 | ) | | (4,758 | ) | | 4,347 |
| | 4,620 |
| | 4,565 |
| Acquisition-related costs | | — |
| | — |
| | — |
| | (185 | ) | | (318 | ) | | (456 | ) | | 3 |
| | 12 |
| | 39 |
| Certain significant items(c) | | — |
| | — |
| | — |
| | 2,481 |
| | (3,719 | ) | | (2,423 | ) | | 36 |
| | 38 |
| | 52 |
| | | $ | 51,750 |
| | $ | 53,647 |
| | $ | 52,546 |
| | $ | 17,682 |
| | $ | 11,885 |
| | $ | 12,305 |
| | $ | 6,010 |
| | $ | 6,384 |
| | $ | 6,269 |
|
| | (a) | Income from continuing operations before provision/(benefit) for taxes on income. Biopharma’s earnings include dividend income from our investment in ViiV of $220 million in 2019, $253 million in 2018 and $266 million in 2017. For additional information, see Note 4. |
| | (b) | Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations. |
| | (c) | Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. |
For Earnings in 2019, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $758 million, (ii) charges for certain legal matters of $543 million, (iii) certain asset impairment charges of $2.8 billion, (iv) charges for business and legal entity alignment of $495 million, (v) net gains of $415 million recognized during the period on equity securities, (vi) a pre-tax gain of $8.1 billion associated with the completion of the GSK Consumer Healthcare joint venture transaction, (vii) net losses on early retirement of debt of $138 million and (viii) other charges of $1.3 billion, which includes, among other things: an upfront license fee payment of $250 million to Akcea, which was recorded in Research and development expenses, charges of $112 million recorded in Other (income)/deductions––net representing our pro rata share of primarily restructuring and business combination accounting charges recorded by the GSK Consumer Healthcare joint venture, a $337 million charge in Research and development expenses related to our acquisition of Therachon, a $99 million charge in Cost of sales related to rivipansel, primarily for inventory manufactured for expected future sale and charges of $240 million, primarily in Selling, informational and administrative expenses and Other (income)/deductions––net, for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity associated with the formation of the GSK Consumer Healthcare joint venture. For additional information, see Note 1A, Note 2A, Note 2C, Note 2D, Note 3 and Note 4. For Earnings in 2018, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $977 million, (ii) net charges for certain legal matters of $157 million, (iii) certain asset impairment charges of $3.1 billion, (iv) charges for business and legal entity alignment of $63 million, (v) net gains of $586 million recognized during the period on equity securities, (vi) net losses on early retirement of debt of $3 million and (vii) other charges of $4 million, which includes, among other things: a non-cash $343 million pre-tax gain in Other (income)/deductions––net associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and pre-clinical stage neuroscience assets primarily targeting disorders of the central nervous system, a $119 million charge, in the aggregate, in Selling, informational and administrative expenses for a special, one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected positive net impact of the December 2017 enactment of the TCJA, and a non-cash $50 million pre-tax gain in Other (income)/deductions––net as a result of the contribution of our allogeneic CAR T cell therapy development program assets in connection with our contribution agreement entered into with Allogene. For additional information, see Note 2B, Note 3 and Note 4. For Earnings in 2017, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $204 million, (ii) charges for certain legal matters of $237 million, (iii) certain asset impairment charges of $379 million, (iv) charges for business and legal entity alignment of $71 million, (v) net gains of $224 million recognized during the period on equity securities, (vi) net losses on early retirement of debt of $999 million and (vii) other charges of $756 million, which includes, among other things: a charitable contribution to the Pfizer Foundation of $200 million, which is included in Selling, informational and administrative expenses, $195 million in inventory losses, overhead costs related to the period in which our Puerto Rico plants were not operational, and incremental costs, all of which resulted from hurricanes in Puerto Rico in 2017 and are included in Cost of sales, an $81 million loss related to the sale of our former 49% equity share in Hisun Pfizer, which is included in Other (income)/deductions––net, charges of $55 million in Other (income)/deductions––net representing adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell and a net loss of $30 million related to the sale of our former 40% ownership investment in Teuto, including the extinguishment of a put option for the remaining 60% ownership interest, which is included in Other (income)/deductions––net. For additional information, see Note 2B, Note 2C, Note 3 and Note 4.
|
| Reconciliation Of Depreciation And Amortization From Segments To Consolidated |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | The following table provides selected income statement information by reportable segment: | | | Revenues | | Earnings(a) | | Depreciation and Amortization(b) | | | Year Ended December 31, | | Year Ended December 31, | | Year Ended December 31, | (MILLIONS OF DOLLARS) | | 2019 |
| | 2018 |
| | 2017 |
| | 2019 |
| | 2018 |
| | 2017 |
| | 2019 |
| | 2018 |
| | 2017 |
| Reportable Segments: | | | | | | | | | | | | | | | | | | | Biopharma | | $ | 39,419 |
| | $ | 37,558 |
| | $ | 35,530 |
| | $ | 24,517 |
| | $ | 23,738 |
| | $ | 22,194 |
| | $ | 958 |
| | $ | 953 |
| | $ | 881 |
| Upjohn | | 10,233 |
| | 12,484 |
| | 13,447 |
| | 6,785 |
| | 8,636 |
| | 9,348 |
| | 105 |
| | 112 |
| | 125 |
| Total reportable segments | | 49,653 |
| | 50,042 |
| | 48,977 |
| | 31,301 |
| | 32,374 |
| | 31,542 |
| | 1,063 |
| | 1,065 |
| | 1,006 |
| Other business activities | | 2,098 |
| | 3,605 |
| | 3,472 |
| | (5,723 | ) | | (5,283 | ) | | (5,302 | ) | | 108 |
| | 146 |
| | 142 |
| Reconciling Items: | | | | | | | | |
| | |
| |
|
| |
|
| |
|
| |
|
| Corporate and other unallocated | | — |
| | — |
| | 97 |
| | (5,859 | ) | | (6,383 | ) | | (6,299 | ) | | 453 |
| | 503 |
| | 465 |
| Purchase accounting adjustments | | — |
| | — |
| | — |
| | (4,333 | ) | | (4,786 | ) | | (4,758 | ) | | 4,347 |
| | 4,620 |
| | 4,565 |
| Acquisition-related costs | | — |
| | — |
| | — |
| | (185 | ) | | (318 | ) | | (456 | ) | | 3 |
| | 12 |
| | 39 |
| Certain significant items(c) | | — |
| | — |
| | — |
| | 2,481 |
| | (3,719 | ) | | (2,423 | ) | | 36 |
| | 38 |
| | 52 |
| | | $ | 51,750 |
| | $ | 53,647 |
| | $ | 52,546 |
| | $ | 17,682 |
| | $ | 11,885 |
| | $ | 12,305 |
| | $ | 6,010 |
| | $ | 6,384 |
| | $ | 6,269 |
|
| | (a) | Income from continuing operations before provision/(benefit) for taxes on income. Biopharma’s earnings include dividend income from our investment in ViiV of $220 million in 2019, $253 million in 2018 and $266 million in 2017. For additional information, see Note 4. |
| | (b) | Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations. |
| | (c) | Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. |
For Earnings in 2019, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $758 million, (ii) charges for certain legal matters of $543 million, (iii) certain asset impairment charges of $2.8 billion, (iv) charges for business and legal entity alignment of $495 million, (v) net gains of $415 million recognized during the period on equity securities, (vi) a pre-tax gain of $8.1 billion associated with the completion of the GSK Consumer Healthcare joint venture transaction, (vii) net losses on early retirement of debt of $138 million and (viii) other charges of $1.3 billion, which includes, among other things: an upfront license fee payment of $250 million to Akcea, which was recorded in Research and development expenses, charges of $112 million recorded in Other (income)/deductions––net representing our pro rata share of primarily restructuring and business combination accounting charges recorded by the GSK Consumer Healthcare joint venture, a $337 million charge in Research and development expenses related to our acquisition of Therachon, a $99 million charge in Cost of sales related to rivipansel, primarily for inventory manufactured for expected future sale and charges of $240 million, primarily in Selling, informational and administrative expenses and Other (income)/deductions––net, for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity associated with the formation of the GSK Consumer Healthcare joint venture. For additional information, see Note 1A, Note 2A, Note 2C, Note 2D, Note 3 and Note 4. For Earnings in 2018, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $977 million, (ii) net charges for certain legal matters of $157 million, (iii) certain asset impairment charges of $3.1 billion, (iv) charges for business and legal entity alignment of $63 million, (v) net gains of $586 million recognized during the period on equity securities, (vi) net losses on early retirement of debt of $3 million and (vii) other charges of $4 million, which includes, among other things: a non-cash $343 million pre-tax gain in Other (income)/deductions––net associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and pre-clinical stage neuroscience assets primarily targeting disorders of the central nervous system, a $119 million charge, in the aggregate, in Selling, informational and administrative expenses for a special, one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected positive net impact of the December 2017 enactment of the TCJA, and a non-cash $50 million pre-tax gain in Other (income)/deductions––net as a result of the contribution of our allogeneic CAR T cell therapy development program assets in connection with our contribution agreement entered into with Allogene. For additional information, see Note 2B, Note 3 and Note 4. For Earnings in 2017, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $204 million, (ii) charges for certain legal matters of $237 million, (iii) certain asset impairment charges of $379 million, (iv) charges for business and legal entity alignment of $71 million, (v) net gains of $224 million recognized during the period on equity securities, (vi) net losses on early retirement of debt of $999 million and (vii) other charges of $756 million, which includes, among other things: a charitable contribution to the Pfizer Foundation of $200 million, which is included in Selling, informational and administrative expenses, $195 million in inventory losses, overhead costs related to the period in which our Puerto Rico plants were not operational, and incremental costs, all of which resulted from hurricanes in Puerto Rico in 2017 and are included in Cost of sales, an $81 million loss related to the sale of our former 49% equity share in Hisun Pfizer, which is included in Other (income)/deductions––net, charges of $55 million in Other (income)/deductions––net representing adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell and a net loss of $30 million related to the sale of our former 40% ownership investment in Teuto, including the extinguishment of a put option for the remaining 60% ownership interest, which is included in Other (income)/deductions––net. For additional information, see Note 2B, Note 2C, Note 3 and Note 4.
|
| Revenue from External Customers by Geographic Areas |
As described in Note 1A, acquisitions impacted our results of operations in 2019 and 2017, the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture impacted our results of operations in 2019 and divestitures impacted our results of operations in 2017. | | | | | | | | | | | | | | The following table provides revenues by geographic area: | | | Year Ended December 31, | (MILLIONS OF DOLLARS) | | 2019 |
| | 2018 |
| | 2017 |
| United States | | $ | 23,852 |
| | $ | 25,329 |
| | $ | 26,026 |
| Developed Europe(a) | | 8,701 |
| | 9,116 |
| | 8,508 |
| Developed Rest of World(b) | | 6,465 |
| | 6,551 |
| | 6,612 |
| Emerging Markets(c) | | 12,733 |
| | 12,651 |
| | 11,399 |
| Revenues | | $ | 51,750 |
| | $ | 53,647 |
| | $ | 52,546 |
|
| | (a) | Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $7.0 billion in 2019, $7.3 billion in 2018 and $6.8 billion in 2017. |
| | (b) | Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand. |
(c) Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.
|
| Long-lived Assets by Geographic Areas |
| | | | | | | | | | | | | | The following table provides long-lived assets by geographic area: | | | As of December 31, | (MILLIONS OF DOLLARS) | | 2019 |
| | 2018 |
| | 2017 |
| Property, plant and equipment, net | | | | | | | United States | | $ | 7,606 |
| | $ | 7,089 |
| | $ | 6,971 |
| Developed Europe(a) | | 4,304 |
| | 4,204 |
| | 4,345 |
| Developed Rest of World(b) | | 453 |
| | 490 |
| | 632 |
| Emerging Markets(c) | | 1,603 |
| | 1,602 |
| | 1,917 |
| Property, plant and equipment, net | | $ | 13,967 |
| | $ | 13,385 |
| | $ | 13,865 |
|
| | (a) | Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. |
| | (b) | Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand. |
(c) Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.
|
| Schedule of Significant Product Revenues |
As described in Note 1A, acquisitions impacted our results of operations in 2019 and 2017, the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture impacted our results of operations in 2019 and divestitures impacted our results of operations in 2017. The following table provides detailed revenue information for several of our major products: | | | | | | | | | | | | | | | | (MILLIONS OF DOLLARS) | | | | Year Ended December 31, | PRODUCT | | PRIMARY INDICATION OR CLASS | | 2019 |
| | 2018 |
| | 2017 |
| TOTAL REVENUES | | | | $ | 51,750 |
| | $ | 53,647 |
| | $ | 52,546 |
| PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA) | | $ | 39,419 |
| | $ | 37,558 |
| | $ | 35,530 |
| Internal Medicine(a) | | $ | 9,119 |
| | $ | 8,869 |
| | $ | 8,229 |
| Eliquis alliance revenues and direct sales | | Nonvalvular Atrial fibrillation, deep vein thrombosis, pulmonary embolism | | 4,220 |
| | 3,434 |
| | 2,523 |
| Chantix/Champix | | An aid to smoking cessation treatment in adults 18 years of age or older | | 1,107 |
| | 1,085 |
| | 997 |
| Premarin family | | Symptoms of menopause | | 734 |
| | 832 |
| | 977 |
| BMP2 | | Development of bone and cartilage | | 287 |
| | 279 |
| | 261 |
| Toviaz | | Overactive bladder | | 250 |
| | 271 |
| | 257 |
| All other Internal Medicine | | Various | | 2,521 |
| | 2,969 |
| | 3,213 |
| Oncology(b) | | $ | 9,014 |
| | $ | 7,471 |
| | $ | 6,304 |
| Ibrance | | Metastatic breast cancer | | 4,961 |
| | 4,118 |
| | 3,126 |
| Sutent | | Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor | | 936 |
| | 1,049 |
| | 1,081 |
| Xtandi alliance revenues | | Non-metastatic and metastatic castration-resistant prostate cancer and non-metastatic castration-sensitive prostate cancer | | 838 |
| | 699 |
| | 590 |
| Xalkori | | ALK-positive and ROS1-positive advanced NSCLC | | 530 |
| | 524 |
| | 594 |
| Inlyta | | Advanced RCC | | 477 |
| | 298 |
| | 339 |
| Bosulif | | Philadelphia chromosome–positive chronic myelogenous leukemia | | 365 |
| | 296 |
| | 233 |
| Retacrit(c) | | Anemia | | 225 |
| | 82 |
| | 67 |
| Mektovi | | In combination with Braftovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation | | 49 |
| | — |
| | — |
| Braftovi | | In combination with Mektovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation | | 48 |
| | — |
| | — |
| All other Oncology | | Various | | 585 |
| | 406 |
| | 274 |
| Hospital(d) | | $ | 7,772 |
| | $ | 7,955 |
| | $ | 8,369 |
| Sulperazon | | Bacterial infections | | 684 |
| | 613 |
| | 471 |
| Medrol(e) | | Anti-inflammatory glucocorticoid | | 469 |
| | 493 |
| | 540 |
| Vfend | | Fungal infections | | 346 |
| | 392 |
| | 421 |
| Zithromax(e) | | Bacterial infections | | 336 |
| | 326 |
| | 299 |
| EpiPen | | Epinephrine injection used in treatment of life-threatening allergic reactions | | 303 |
| | 303 |
| | 290 |
| Fragmin | | Treatment/prevention of venous thromboembolism | | 253 |
| | 293 |
| | 306 |
| Zyvox | | Bacterial infections | | 251 |
| | 236 |
| | 281 |
| Zosyn/Tazocin | | Bacterial infections | | 200 |
| | 230 |
| | 195 |
| Tygacil | | Bacterial infections | | 197 |
| | 249 |
| | 260 |
| Diflucan | | Fungal infections | | 190 |
| | 189 |
| | 180 |
| Panzyga | | Primary humoral immunodeficiency | | 183 |
| | 39 |
| | — |
| Pfizer CentreOne(f) | | Various | | 810 |
| | 755 |
| | 706 |
| All other Anti-infectives | | Various | | 1,114 |
| | 1,041 |
| | 1,237 |
| All other Hospital(d) | | Various | | 2,436 |
| | 2,797 |
| | 3,182 |
| Vaccines | | $ | 6,504 |
| | $ | 6,332 |
| | $ | 6,001 |
| Prevnar 13/Prevenar 13 | | Pneumococcal disease | | 5,847 |
| | 5,802 |
| | 5,601 |
| Nimenrix | | Meningococcal disease | | 230 |
| | 140 |
| | 86 |
| FSME/IMMUN-TicoVac | | Tick-borne encephalitis disease | | 220 |
| | 184 |
| | 134 |
| Trumenba | | Meningococcal disease | | 135 |
| | 116 |
| | 88 |
| All other Vaccines | | Various | | 73 |
| | 90 |
| | 91 |
| Inflammation & Immunology (I&I)(g) | | $ | 4,733 |
| | $ | 4,720 |
| | $ | 4,386 |
| Xeljanz | | RA, PsA, UC | | 2,242 |
| | 1,774 |
| | 1,345 |
| Enbrel (Outside the U.S. and Canada) | | RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis | | 1,699 |
| | 2,112 |
| | 2,452 |
| Inflectra/Remsima(c), (g) | | Crohn’s Disease, Pediatric Crohn’s Disease, UC, Pediatric UC, RA in combination with methotrexate, Ankylosing Spondylitis, PsA and Plaque Psoriasis | | 625 |
| | 642 |
| | 419 |
| Eucrisa | | Mild-to-moderate atopic dermatitis (eczema) in adults and children 2 years of age and older | | 138 |
|
| 147 |
|
| 67 |
| All other I&I | | Various | | 29 |
| | 45 |
| | 103 |
|
| | | | | | | | | | | | | | | | (MILLIONS OF DOLLARS) | | | | Year Ended December 31, | PRODUCT | | PRIMARY INDICATION OR CLASS | | 2019 |
| | 2018 |
| | 2017 |
| Rare Disease | | $ | 2,278 |
| | $ | 2,211 |
| | $ | 2,240 |
| Genotropin | | Replacement of human growth hormone | | 498 |
| | 558 |
| | 532 |
| BeneFIX | | Hemophilia B | | 488 |
| | 554 |
| | 604 |
| Vyndaqel/Vyndamax | | ATTR-Cardiomyopathy and Polyneuropathy | | 473 |
| | 148 |
| | 124 |
| Refacto AF/Xyntha | | Hemophilia A | | 426 |
| | 514 |
| | 551 |
| Somavert | | Acromegaly | | 264 |
| | 267 |
| | 254 |
| All other Rare Disease | | Various | | 129 |
| | 170 |
| | 176 |
| Upjohn(a) | | $ | 10,233 |
| | $ | 12,484 |
| | $ | 13,447 |
| Lyrica | | Epilepsy, post-herepetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic pain due to spinal cord injury | | 3,321 |
| | 4,970 |
| | 5,065 |
| Lipitor | | Reduction of LDL cholesterol | | 1,973 |
| | 2,062 |
| | 1,915 |
| Norvasc | | Hypertension | | 950 |
| | 1,029 |
| | 932 |
| Celebrex | | Arthritis pain and inflammation, acute pain | | 719 |
| | 686 |
| | 775 |
| Viagra | | Erectile dysfunction | | 497 |
| | 636 |
| | 1,204 |
| Effexor | | Depression and certain anxiety disorders | | 336 |
| | 311 |
| | 297 |
| Zoloft | | Depression and certain anxiety disorders | | 294 |
| | 298 |
| | 291 |
| Xalatan/Xalacom | | Glaucoma and ocular hypertension | | 281 |
| | 318 |
| | 335 |
| Xanax | | Anxiety disorders | | 198 |
| | 223 |
| | 225 |
| Revatio | | Pulmonary arterial hypertension | | 144 |
| | 227 |
| | 252 |
| All other Upjohn | | Various | | 1,519 |
| | 1,725 |
| | 2,158 |
| Consumer Healthcare Business(h) | | $ | 2,098 |
| | $ | 3,605 |
| | $ | 3,472 |
| Other(i) | | Various | | $ | — |
| | $ | — |
| | $ | 97 |
| Total Alliance revenues | | Various | | $ | 4,648 |
| | $ | 3,838 |
| | $ | 2,927 |
| Total Biosimilars(c) |
| Various |
| $ | 911 |
|
| $ | 769 |
|
| $ | 531 |
| Total Sterile Injectable Pharmaceuticals(j) | | $ | 5,035 |
| | $ | 5,214 |
| | $ | 5,673 |
|
| | (a) | We reclassified certain products from the LEP category, including Premarin family products, and certain other products from the legacy Peri-LOE category, including Pristiq, to the Internal Medicine category and reclassified Lyrica from the Internal Medicine category to the Upjohn business to conform 2018 and 2017 product revenues to the current presentation. |
| | (b) | We performed certain reclassifications in the All other Oncology category to conform 2018 and 2017 product revenues to the current presentation. |
| | (c) | Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima and Retacrit. |
| | (d) | Hospital is a business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. We performed certain reclassifications, primarily from the legacy SIP category (Sulperazon, Medrol, Fragmin, Tygacil, Zosyn/Tazocin and Precedex, among other products), the LEP category (Epipen and Zithromax), and the legacy Peri-LOE category (Vfend and Zyvox) to the Hospital category to conform 2018 and 2017 product revenues to the current presentation. Hospital also includes Pfizer CentreOne(f). All other Hospital primarily includes revenues from legacy SIP products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in “All other Anti-infectives”. |
| | (e) | 2018 and 2017 revenues for Medrol and Zithromax may not agree to previously disclosed revenues because revenues for those products were previously split between LEP and the legacy SIP categories. All revenues for these products are currently reported in the Hospital category. |
| | (f) | Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis Inc. In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within legacy All Other LEP and legacy All Other SIP, are reported in emerging markets within Pfizer CentreOne. |
| | (g) | We reclassified Inflectra/Remsima from the legacy Biosimilars category to the Inflammation & Immunology category to conform 2018 and 2017 product revenues to the current presentation. |
| | (h) | On July 31, 2019, Pfizer’s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK’s consumer healthcare business to form a new consumer healthcare joint venture. For additional information, see Note 1A and Note 2C. |
| | (i) | Represents HIS revenues through February 2, 2017, which includes Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets. On February 3, 2017, we completed the sale of HIS to ICU Medical. For additional information, see Note 1A and Note 2B. |
(j) Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital business, including anti-infective sterile injectable pharmaceuticals.
|